Vor Biopharma (VOR) Net Income towards Common Stockholders (2020 - 2026)

Vor Biopharma (VOR) has reported Net Income towards Common Stockholders for 7 consecutive years, with -$31.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 3.54% year-over-year to -$31.3 million; the TTM figure through Mar 2026 stood at -$2.5 billion (down 1937.7% YoY), while the FY2025 annual figure was -$598.5 million, down 133.68% from the prior year.
• Net Income towards Common Stockholders rose to -$31.3 million in Q1 2026 per VOR's latest filing, from -$33.3 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$21.7 million in Q2 2022 and bottomed at -$1.6 billion in Q2 2025.
• Historically, Net Income towards Common Stockholders has averaged -$165.4 million across 5 years, with a median of -$30.0 million in 2023.
• Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders increased 16.97% — and 2025, when it slumped 5552.75%.
• Vor Biopharma's Net Income towards Common Stockholders stood at -$23.9 million in 2022, then retreated by 9.83% to -$26.3 million in 2023, then slipped by 23.37% to -$32.4 million in 2024, then decreased by 2.71% to -$33.3 million in 2025, then increased by 5.83% to -$31.3 million in 2026.
• Business Quant data shows VOR's Net Income towards Common Stockholders at -$31.3 million in Q1 2026, -$33.3 million in Q4 2025, and -$812.7 million in Q3 2025.